Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

44.66 +0.03 (+0.07%)
Streaming Delayed Price Updated: 3:44 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,417,587
Open 50.45
Bid (Size) 44.65 (400)
Ask (Size) 44.75 (900)
Prev. Close 44.63
Today's Range 44.17 - 52.50
52wk Range 35.51 - 59.68
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical... 
Via MarketBeat
Topics Earnings

Performance

YTD
-9.7%
-9.7%
1 Month
-5.5%
-5.5%
3 Month
-8.2%
-8.2%
6 Month
-8.4%
-8.4%
1 Year
+20.5%
+20.5%

More News

Read More
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
Via StockStory
News headline image
Supernus Announces Second Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Via StockStory
Topics Artificial Intelligence
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
Via StockStory
News headline image
1 Growth Stock to Stash and 2 We Turn Down
Via StockStory
Topics Artificial Intelligence
News headline image
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
Via StockStory
News headline image
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in June Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Stocks Under $50 with Open Questions
Via StockStory
News headline image
3 Small-Cap Stocks That Concern Us
Via StockStory
Topics Artificial Intelligence
News headline image
3 Growth Stocks We Approach with Caution
Via StockStory
News headline image
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
Via StockStory
Topics Earnings Supply Chain
News headline image
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Via StockStory
Topics Earnings Economy
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges
Via StockStory
Topics Economy Supply Chain
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
Via StockStory

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 44.66
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 08/03/26 03:44 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.37B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>